Company Description
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care.
The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults.
Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014.
The company was founded in 1983 and is headquartered in Cary, North Carolina.
| Country | United States |
| Founded | 1983 |
| IPO Date | Aug 26, 1987 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 128 |
| CEO | Craig Collard |
Contact Details
Address: 100 Regency Forest Drive, Suite 300 Cary, North Carolina 27518 United States | |
| Phone | 858 251 4400 |
| Website | herontx.com |
Stock Details
| Ticker Symbol | HRTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000818033 |
| CUSIP Number | 427746102 |
| ISIN Number | US4277461020 |
| Employer ID | 94-2875566 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Craig Alexander Collard | Chief Executive Officer and Director |
| Ira Duarte | Executive Vice President and Chief Financial Officer |
| Mark E. Hensley | Executive Vice President and Chief Operating Officer |
| Dr. William P. Forbes Pharm. D., Pharm.D. | Executive Vice President and Chief Development Officer |
| Melissa Jarel | Executive Director of Legal |
| Ryan Craig | Vice President of Marketing |
| John Aiken | Executive Director of People Management and Training |
| Dr. John C. Arthur Ph.D. | Senior Vice President of Manufacturing and Supply |
| Robert Sullivan | Senior Vice President of Oncology Care Franchise and Commercial Operations |
| Brett Fleshman | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2026 | SCHEDULE 13G/A | Filing |
| May 11, 2026 | 10-Q | Quarterly Report |
| May 11, 2026 | 8-K | Current Report |
| Apr 30, 2026 | ARS | Filing |
| Apr 30, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 20, 2026 | PRE 14A | Other preliminary proxy statements |
| Apr 6, 2026 | 8-K | Current Report |
| Mar 27, 2026 | SCHEDULE 13G/A | Filing |
| Feb 26, 2026 | 10-K | Annual Report |